Questões de Concurso
Sobre tradução | translation em inglês
Foram encontradas 550 questões
That affirmation is correctly translated into English in
The expression the world’s sixth-largest economy from that statement is correctly translated into Portuguese in
Using your phone while on the toilet poses significant health risks, as warned by an expert, Dr. Sethi. Despite being a common habit, mindlessly scrolling or using your phone in the bathroom can lead to severe consequences. Dr. Sethi, a Harvard-trained stomach doctor, highlights that this practice, particularly during bowel movements, causes extended sitting that strains the rectum and anus, potentially resulting in hemorrhoids, anal fissures, and rectal prolapse.
Furthermore, using phones in the bathroom makes them a breeding ground for bacteria, surpassing the hygiene levels of a public toilet seat. Dr. Sethi emphasizes the importance of avoiding phone usage while on the toilet or, if unavoidable, suggests disinfecting the phone afterward. Research spanning over a decade has consistently shown that phones harbor a significant amount of germs, including fecal matter.
Despite these health warnings, over 65% of adults take their phones into the bathroom, with Spain having the highest usage rates (nearly 80%) and Germany the lowest (just under 55%). Interestingly, younger age groups, particularly those aged 26-41 and 18-25, are most likely to engage in this unhygienic behavior. Apart from health concerns, there’s the practical risk of dropping the phone into the toilet, with a fifth of respondents in the United States admitting to this mishap.
Internet: <www.mirror.co.uk> (adapted).
Based on the previous text, judge the following item.
The correct translation of the excerpt “Furthermore, using
phones in the bathroom makes them a breeding ground for
bacteria” to Portuguese is Além disso, usar telefones no
banheiro faz deles um terreno fértil para bactérias.
The English translation of the Portuguese sentence Quanto mais você adia o despertador, menos você quer se levantar da cama is How much more you snooze your alarm, how much less you want to get out of bed.
Marque a alternativa que corresponde à tradução da frase abaixo.
O SUPER HOMEM SALVOU A VIDA DAQUELA
MULHER ONTEM.
Assinalar a alternativa que apresenta a tradução CORRETA para o trecho abaixo:
The children are playing at the park, and I’m cooking dinner.
TEXT III – Tema: As novas tecnologias na sala de aula de Língua Inglesa
Is Technology Taking Over Classrooms?
(Available from: https://citedatthecrossroads.net/eng101f13/2013/10/27/is-technology-taking-over-classrooms/ Accessed on July 8th , 2023)
In the continuation of Text 3, choose the option that best completes it to answer the question.
The _________ is Internet access. But low earth orbit satellites may soon change everything. With this revolutionary new technology, poor telephone communications will be a thing of the past and suddenly being rural won't matter.
The hard cell
Thanks to politics, stem cell research in the United States is suffering. But not so in Sweden, which is poised to capture what could be the biggest new market to hit biotech in a decade.
By Stephan Herrera
February 13, 2003
New York, January 1, 2006:
Sweden announces that one of its biotechnology companies is the first in the world to enter clinical trials with a new drug that could cure Alzheimer's disease. Four years ago this type of research was all but stopped in the United States by political and ethical questions − which is ...61... Sweden now seems in the best position to capture a $25 billion market.
Any day now, the U.S. Congress is expected to pass a sweeping new law that could dramatically inhibit researchers from working with stem cells taken from human embryos. Such cells, which can be used to grow a whole host of new cells and organs, could fundamentally change the way we treat heretofore intractable maladies like Alzheimer's disease, Parkinson's disease, cancer, stroke, liver failure, and heart disease. The only problem is that these cells by definition are derived from human embryos, many of which are cloned or come from unused fetuses collected at fertility clinics. The argument, from a certain segment of the American political spectrum, is that ...62... methods are morally wrong. They are ...63... a form of abortion or an activity that could eventually lead to human cloning.
Those working in stem cell research say the short-term effect of the legislation will be to further chill all forms of scientific inquiry and commercialization efforts in the field. Entrepreneurs and investors are already eschewing such research − in large part because of the additional uncertainty and risk that politics introduce.
Of the nearly 50 private stem cell companies in the United States, only a handful are still viable. Meanwhile, across the Atlantic, Sweden has avoided many of the political and ethical quagmires surrounding this type of research. It currently has 40 private stem cell companies, a number that's growing. Sweden's leading research universities have 32 percent of the world's stem cell inventory, close on the heels of the United States' 35 percent.
Sweden, say analysts, is now in the best position to
capture a worldwide market for drugs based on stem cell
therapies that could grow to $25 billion in the next three to five
years − nearly equal to the whole biotech industry at present.
This estimate doesn't even address the market for stem cells
capable of repairing damaged vital organs like the brain, heart,
and kidneys. If the United States offers an object lesson of what
can happen when scientific inquiry and investment capital fall victim to politics, Sweden and its leading stem cell startup,
NeuroNova, offer the opposite example. How odd that the
United States, which for generations has been the envy of the
world for its progressive views of science and commercialization,
should now have a biomedical climate chillier than a Swedish
winter.
One company feeling a lot of pain is StemCells, which at first glance seems to have it all: founding scientists include Stanford's Dr. Weissman and Fred Gage of the Salk Institute in La Jolla, California. An equally well-regarded expert in the treatment of Alzheimer's, Dr. Gage spent five years in Sweden as a researcher and now sits on a national committee on stem cell research there. The firm's chairman is Roger Perlmutter, Amgen's head of research.
Yet over the past two years, none of management's efforts to help investors and even critics reconsider the stem cell field have worked. At press time, the stock was thinly traded and sitting in the neighborhood of 50 cents. With less than $15 million in cash, the company likely won't exist at this time next year. (CEO Martin McGlynn, who joined the firm in January 2001, would not talk to Red Herring, despite repeated efforts.)
Some observers on Wall Street are asking, If StemCells can't make it, who can? Geron, the only other publicly held stem cell firm to speak of, is in a fix, too. The company's stock price is also moribund, at $3.85 per share. Thanks to some capital infusions a few years ago, when money came easy, Geron still has $40 million on hand, but by the end of next year, that too will likely be gone. Once a media darling, Geron focuses on diagnostic tests and drugs derived from stem cells, a strategy that's not going well. For the nine months ended last September, revenue fell 68 percent to $955,000 and net loss widened 18 percent to $26.7 million. The company's financials were also hit hard after it terminated an agreement with Pharmacia and acquired research technology from Lynx Therapeutics, which Geron bought in a desperate attempt to be seen as something more than just a stem cell company.
The situation is quite different, however, for Sweden's NeuroNova, which has 30 academic partners and a staff of 20. NeuroNova is working on ways to inject stem cells into the human brain to trigger a process called neurogenesis (the growth of new neural cells), which could combat diseases like Parkinson's, Alzheimer's, and even schizophrenia.
If NeuroNova is the first to develop a drug capable of
treating one of several central nervous system disorders − by far
the most lucrative after heart disease products − it will have
done so not because it raised more money or got more media
buzz than the rest. It will have succeeded because the science
is solid, and academe, government, and the investment
community are supportive. Meanwhile, the United States will
look on with envy and wonder how it, a country known for its
entrepreneurial innovation, ever got so short-sighted.
(Adapted from
http://www.redherring.com/investor/2003/02/biotech021303.html)
Conheça nossos planos